These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38924184)

  • 1. Emicizumab plasma levels after accelerated saturation in acquired haemophilia A.
    Kloeter T; Keller M; Metze M; Petros S; Pfrepper C
    Haemophilia; 2024 Jun; ():. PubMed ID: 38924184
    [No Abstract]   [Full Text] [Related]  

  • 2. Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study.
    Tiede A; Hart C; Knöbl P; Greil R; Oldenburg J; Sachs UJ; Miesbach W; Pfrepper C; Trautmann-Grill K; Holstein K; Pilch J; Möhnle P; Schindler C; Weigt C; Schipp D; May M; Dobbelstein C; Pelzer FJ; Werwitzke S; Klamroth R
    Lancet Haematol; 2023 Nov; 10(11):e913-e921. PubMed ID: 37858328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma.
    Grandoni J; Duretz V; Bonzo D; Evans S; Plantier JL
    Haemophilia; 2021 Mar; 27(2):321-328. PubMed ID: 33550714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulation for Stroke Prevention after Restoration of Haemostasis with Emicizumab in Acquired Haemophilia A.
    Al-Banaa K; Gallastegui-Crestani N; von Drygalski A
    Eur J Case Rep Intern Med; 2021; 8(11):002984. PubMed ID: 34912741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emicizumab in the Treatment of Acquired Haemophilia: A Case Report.
    Möhnle P; Pekrul I; Spannagl M; Sturm A; Singh D; Dechant C
    Transfus Med Hemother; 2019 Apr; 46(2):121-123. PubMed ID: 31191199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world data on the use of emicizumab in patients with haemophilia A with and without inhibitors in Singapore.
    Lee MW; Cheong MA; Ng HJ; Tien SL; Lam JCM
    Ann Acad Med Singap; 2023 Nov; 52(11):580-589. PubMed ID: 38920147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow-up from the UK Haemophilia Centre Doctors' Organisation (UKHCDO).
    Wall C; Xiang H; Palmer B; Chalmers E; Chowdary P; Collins PW; Fletcher S; Hall GW; Hart DP; Mathias M; Sartain P; Shapiro S; Stephensen D; Talks K; Hay CRM;
    Haemophilia; 2023 May; 29(3):743-752. PubMed ID: 36811304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emicizumab for acquired haemophilia A: A case series.
    Engelen MM; Vandesande J; De Bent J; Van Laer C; Labarque V; Jacquemin M; Peerlinck K; Hermans C; Verhamme P; Vanassche T
    Haemophilia; 2023 Jul; 29(4):1049-1055. PubMed ID: 37276345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays.
    Kizilocak H; Marquez-Casas E; Malvar J; Carmona R; Young G
    Haemophilia; 2021 Sep; 27(5):730-735. PubMed ID: 34115433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.
    Batsuli G; Zimowski KL; Tickle K; Meeks SL; Sidonio RF
    Haemophilia; 2019 Sep; 25(5):789-796. PubMed ID: 31373431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature.
    Thomas VM; Abou-Ismail MY; Lim MY
    Haemophilia; 2022 Jan; 28(1):4-17. PubMed ID: 34820989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emicizumab in acquired haemophilia A: about two clinical cases and literature review.
    Hansenne A; Hermans C
    Ther Adv Hematol; 2021; 12():20406207211038193. PubMed ID: 34471508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK.
    Kragh N; Tytula A; Pochopien M; Aballéa S; Toumi M; Hakimi Z; Nazir J; Bystrická L; Fatoye F
    Eur J Haematol; 2023 Mar; 110(3):262-270. PubMed ID: 36398467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Assessment of the budgetary impact of an emicizumab therapy introduction for patients with severe haemophilia A without inhibitor].
    Oka G; Pieragostini R; Roussel-Robert V; Paubel P; Degrassat-Theas A; Lopez I
    Ann Pharm Fr; 2023 May; 81(3):529-537. PubMed ID: 36375527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world cost estimates of initiating emicizumab in US patients with haemophilia A.
    Samelson-Jones BJ; Guelcher C; Kuhn J; Butler R; Massey G; Guerrera MF; Raffini L
    Haemophilia; 2021 Jul; 27(4):591-598. PubMed ID: 34050689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emicizumab: A Review in Haemophilia A.
    Blair HA
    Drugs; 2019 Oct; 79(15):1697-1707. PubMed ID: 31542880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.
    Yada K; Nogami K; Shinozawa K; Kitazawa T; Hattori K; Amano K; Fukutake K; Shima M
    Br J Haematol; 2018 Oct; 183(2):257-266. PubMed ID: 30125997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approximation of emicizumab plasma levels in emergency situations. A practical approach.
    Pekrul I; Pfrepper C; Calatzis G; Giebl A; Siegemund A; Grützner S; Spannagl M
    Haemophilia; 2021 Mar; 27(2):e214-e220. PubMed ID: 33522651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.